How would you counsel about DMT options for disease-modifying therapy for a patient with multiple sclerosis and positive Hepatitis B surface antigen with negative HBV DNA PCR?

This is mainly an issue when considering B-cell-depleting medicines, alemtuzumab, and cladribine.

For this situation (sAg positive), I would refer to Infectious Disease for their input and co-manage. The patient may need to be on chronic antivirals during immunotherapy, at least for the above medica...